Figure 6.
Figure 6. TfrcAlb-Cre mice respond appropriately to holo-transferrin. Eight-week-old female TfrcAlb-Cre mice and control Tfrcfl/fl littermates (n = 10 for each genotype; n = 5 for each treatment) were injected IV with 10 mg of human apo- or holo-transferrin. The animals were euthanized 5 hours later. Sera were prepared for analysis of iron (A), TIBC (B), transferrin saturation (C), and ferritin (D). Livers were dissected and used to analyze LIC (E), Hamp mRNA (F), Hamp/LIC ratios (G), Tfr1 mRNA (H), Bmp6 mRNA (I), and Id1 mRNA (J). All data are mean ± standard error of the mean. Statistically significant differences across genotypes are indicated by P values and across treatment (apo- vs holo-transferrin) by *P < .05 or ***P < .001, 2-way ANOVA.

TfrcAlb-Cremice respond appropriately to holo-transferrin. Eight-week-old female TfrcAlb-Cre mice and control Tfrcfl/fl littermates (n = 10 for each genotype; n = 5 for each treatment) were injected IV with 10 mg of human apo- or holo-transferrin. The animals were euthanized 5 hours later. Sera were prepared for analysis of iron (A), TIBC (B), transferrin saturation (C), and ferritin (D). Livers were dissected and used to analyze LIC (E), Hamp mRNA (F), Hamp/LIC ratios (G), Tfr1 mRNA (H), Bmp6 mRNA (I), and Id1 mRNA (J). All data are mean ± standard error of the mean. Statistically significant differences across genotypes are indicated by P values and across treatment (apo- vs holo-transferrin) by *P < .05 or ***P < .001, 2-way ANOVA.

Close Modal

or Create an Account

Close Modal
Close Modal